Transplant Immunology: Why the Body Rejects Foreign Organs and How Medicine Prevents It

The Immunological Basis of Graft Rejection

Transplant rejection occurs because the recipient's immune system recognizes the donor organ as foreign, primarily through differences in HLA (human leukocyte antigen) molecules between donor and recipient. Because HLA genes are the most polymorphic in the human genome, the probability that two unrelated individuals share identical HLA types at all loci is extremely small. Even a single HLA mismatch can trigger a potent T cell response, because the foreign HLA molecule looks dramatically different from self-HLA to the recipient's T cell receptors.

T cells recognize donor HLA molecules through two distinct pathways. In direct allorecognition, recipient T cells bind directly to intact donor HLA molecules on the surface of donor cells. This is unusual in immunology, because T cells normally only recognize peptides presented by self-MHC molecules. The reason direct recognition works is that foreign MHC molecules structurally resemble self-MHC carrying a foreign peptide, so T cells whose receptors would normally ignore self-MHC react strongly to the foreign molecule. An estimated 1 to 10 percent of the total T cell repertoire can recognize any given foreign HLA molecule, a remarkably high frequency compared to the roughly 1 in 100,000 to 1 in 1,000,000 frequency of T cells specific for any individual microbial antigen. This high precursor frequency explains why transplant rejection is such a powerful immune response.

In indirect allorecognition, recipient antigen-presenting cells phagocytose shed donor HLA molecules and other donor proteins, process them into peptide fragments, and present those fragments on recipient MHC class II molecules to recipient CD4+ helper T cells. This pathway operates through the same mechanism the immune system uses to respond to any foreign protein and becomes increasingly important in chronic rejection, where it drives the slow, progressive damage to the graft that occurs over months to years even with immunosuppression.

A third pathway, semidirect allorecognition, involves the transfer of intact donor HLA molecules from donor cells to recipient antigen-presenting cells through cell-to-cell contact or extracellular vesicles. The recipient APC then displays both donor MHC (stimulating direct recognition) and processed donor peptides on self-MHC (stimulating indirect recognition) simultaneously, potentially activating a broader T cell response than either pathway alone.

Types of Transplant Rejection

Transplant rejection is classified into three types based on timing and underlying mechanism, and each presents distinct clinical challenges.

Hyperacute rejection occurs within minutes to hours after transplantation and is caused by pre-existing antibodies in the recipient's blood that recognize donor HLA molecules or ABO blood group antigens on the graft vasculature. These antibodies activate complement, triggering massive endothelial damage, thrombosis, and hemorrhagic necrosis of the graft. Hyperacute rejection is essentially an antibody-mediated inflammatory catastrophe that destroys the organ before it can function. It was a major barrier to transplantation in the early days of the field but has been virtually eliminated by pre-transplant crossmatch testing, in which recipient serum is tested for antibodies reactive against donor cells. If the crossmatch is positive, the transplant does not proceed.

Pre-existing donor-reactive antibodies can form through prior blood transfusions, pregnancies (the fetus carries paternal HLA antigens that can sensitize the mother), or previous transplants. Highly sensitized patients, those with antibodies against a broad panel of HLA antigens, face significant difficulty finding a compatible donor. Desensitization protocols using plasmapheresis (to remove existing antibodies), intravenous immunoglobulin, and B cell-depleting agents can reduce antibody levels enough to permit transplantation in some cases, though the risk of antibody-mediated rejection remains elevated.

Acute rejection typically occurs within days to months after transplantation and is driven primarily by T cells that have been activated by donor alloantigens. Acute cellular rejection involves infiltration of the graft by recipient CD4+ and CD8+ T cells, which directly attack donor cells and recruit macrophages through cytokine release. Acute antibody-mediated rejection involves the formation of new donor-specific antibodies (de novo DSA) that damage the graft endothelium through complement activation and antibody-dependent cellular cytotoxicity. Acute rejection episodes can usually be reversed with intensified immunosuppression, typically high-dose corticosteroids for cellular rejection or plasma exchange and anti-B cell therapy for antibody-mediated rejection.

Chronic rejection develops over months to years and is the leading cause of late graft failure. It is characterized by progressive fibrosis and arterial thickening (transplant vasculopathy) that gradually reduces blood flow to the organ. In kidney transplants, chronic rejection manifests as chronic allograft nephropathy with progressive decline in renal function. In heart transplants, it appears as cardiac allograft vasculopathy, a diffuse narrowing of the coronary arteries. Chronic rejection involves both immune (ongoing indirect allorecognition, donor-specific antibodies) and non-immune (ischemia-reperfusion injury, drug toxicity, hypertension) factors. Once established, chronic rejection is largely irreversible with current therapies, and eventually necessitates retransplantation or return to dialysis or other support.

HLA Matching and Donor Selection

HLA matching between donor and recipient remains a cornerstone of transplant medicine, though its importance varies by organ type. For kidney transplantation, matching at HLA-A, HLA-B, and HLA-DR improves long-term graft survival. A "zero-mismatch" kidney (matched at all six alleles: two A, two B, two DR) has significantly better outcomes than a mismatched graft. The United Network for Organ Sharing (UNOS) in the United States gives allocation priority to zero-mismatch kidneys, even across geographic regions, because the survival benefit is substantial.

For liver transplantation, HLA matching is less critical because the liver is relatively resistant to rejection, likely due to its unique immunological properties including a resident population of tolerogenic dendritic cells and liver sinusoidal endothelial cells that can induce T cell tolerance. Liver allocation is based primarily on medical urgency (MELD score) rather than HLA matching. Heart and lung transplants are intermediate: HLA matching improves outcomes but is often not achievable given the urgency of transplantation and the short preservation time of these organs (4 to 6 hours for hearts, compared to 24 to 36 hours for kidneys).

For bone marrow (hematopoietic stem cell) transplantation, HLA matching is critical because donor immune cells in the graft can attack the recipient's tissues, a complication called graft-versus-host disease (GVHD). High-resolution matching at HLA-A, HLA-B, HLA-C, HLA-DRB1, and HLA-DQB1 (10/10 match) is the standard for unrelated donor selection. Even a single mismatch at any of these loci increases the risk of severe GVHD and transplant-related mortality. The Be The Match registry in the United States contains over 23 million typed donors, but finding a 10/10 match remains challenging for patients from underrepresented ethnic groups whose HLA allele frequencies are less well represented in the registry.

Immunosuppressive Therapy

All solid organ transplant recipients require lifelong immunosuppressive therapy to prevent rejection. Modern immunosuppressive regimens typically use a combination of drugs that target different steps in the T cell activation pathway, allowing lower doses of each individual drug and reducing the side effects associated with any single agent.

Calcineurin inhibitors (CNIs), including cyclosporine and tacrolimus, remain the backbone of most transplant immunosuppressive regimens. They work by blocking calcineurin, a phosphatase that activates the transcription factor NFAT, which is required for IL-2 gene transcription. Without IL-2, T cells cannot proliferate in response to antigen recognition. Tacrolimus is approximately 100 times more potent than cyclosporine and has become the preferred CNI in most transplant programs. The major limitation of CNIs is nephrotoxicity: the drugs cause chronic damage to the kidney's tubular and vascular structures, contributing to chronic allograft nephropathy in kidney transplants and causing renal impairment in recipients of other organs.

Mycophenolate mofetil (CellCept) or mycophenolic acid (Myfortic) inhibits inosine monophosphate dehydrogenase, an enzyme essential for de novo purine synthesis. Lymphocytes depend heavily on de novo purine synthesis for proliferation, while most other cell types can use the salvage pathway, giving mycophenolate relative selectivity for lymphocytes. It is used as a maintenance agent in combination with a CNI and corticosteroids in the standard "triple therapy" regimen.

Corticosteroids (prednisone, methylprednisolone) have broad anti-inflammatory and immunosuppressive effects, inhibiting NF-kB signaling and reducing the production of multiple pro-inflammatory cytokines. High-dose intravenous methylprednisolone is the first-line treatment for acute cellular rejection episodes. Long-term corticosteroid use causes a well-known constellation of side effects including weight gain, diabetes, osteoporosis, cataracts, hypertension, and adrenal suppression. Many transplant programs now use steroid-sparing or steroid-withdrawal protocols to minimize these complications.

mTOR inhibitors (sirolimus, everolimus) block the mammalian target of rapamycin, a kinase that controls cell proliferation, metabolism, and survival. They are used as alternatives to CNIs in patients with nephrotoxicity or as adjuncts in patients with certain malignancies, because mTOR inhibitors have anti-tumor properties. Biologic agents including basiliximab (anti-IL-2 receptor antibody), used as induction therapy, and belatacept (CTLA-4-Ig fusion protein), which blocks T cell co-stimulation, represent newer approaches that provide effective immunosuppression with different side effect profiles.

Graft-Versus-Host Disease

Graft-versus-host disease (GVHD) is a unique complication of bone marrow and hematopoietic stem cell transplantation in which donor immune cells, primarily donor T cells, attack the recipient's tissues. GVHD does not occur in solid organ transplants because the number of donor immune cells transferred with the organ is insufficient to mount a sustained attack against the recipient's tissues (the recipient's immune system vastly outnumbers donor passenger lymphocytes and eliminates them). In bone marrow transplantation, however, the donor immune system replaces the recipient's, and if donor T cells recognize recipient tissues as foreign, they will attack them.

Acute GVHD typically develops within the first 100 days after transplantation and primarily affects three organ systems: the skin (causing a maculopapular rash that can progress to blistering and desquamation), the liver (causing jaundice due to bile duct damage), and the gastrointestinal tract (causing diarrhea, abdominal pain, and mucosal ulceration). Severity is graded from I to IV, with grade IV being life-threatening. Treatment involves high-dose corticosteroids, and steroid-refractory acute GVHD has a mortality rate exceeding 80 percent. The JAK1/JAK2 inhibitor ruxolitinib was approved in 2019 for steroid-refractory acute GVHD and has improved outcomes significantly.

Chronic GVHD develops after 100 days and affects approximately 30 to 70 percent of long-term bone marrow transplant survivors. It resembles autoimmune diseases in its clinical features, with fibrotic changes affecting the skin (scleroderma-like tightening), mouth (mucosal ulceration and dryness), eyes (severe dry eyes), lungs (bronchiolitis obliterans), joints, and other organs. Chronic GVHD significantly impairs quality of life and requires prolonged immunosuppressive therapy, often for years.

Paradoxically, a mild degree of GVHD in leukemia patients receiving bone marrow transplants is actually beneficial. The donor T cells that cause GVHD can also recognize and destroy residual leukemia cells, an effect called graft-versus-leukemia (GVL). Patients with mild GVHD have lower relapse rates than patients with no GVHD at all, and the deliberate manipulation of donor T cell activity to maximize GVL while minimizing GVHD is an active area of transplant research.

The Quest for Transplant Tolerance

The ultimate goal of transplant immunology is the induction of tolerance, a state in which the recipient's immune system specifically accepts the donor organ without requiring ongoing immunosuppressive therapy, while maintaining normal immune responses against infections and tumors. True tolerance would eliminate the infection risk, cancer risk, drug side effects, and expense of lifelong immunosuppression.

Tolerance occurs naturally in several settings. Identical twins accept transplants from each other without immunosuppression because their HLA molecules are identical (syngeneic transplants). The liver is partially tolerogenic, and some liver transplant recipients can be safely weaned off immunosuppression years after transplantation, a phenomenon called operational tolerance. In animal models, tolerance can be reliably induced through mixed chimerism (transplanting donor bone marrow alongside the organ, creating a recipient whose immune system contains both donor and recipient cells), co-stimulation blockade, or regulatory T cell therapy.

Several clinical protocols have achieved tolerance in small numbers of kidney transplant recipients. The most successful approach involves combined kidney and bone marrow transplantation from the same living donor, with a conditioning regimen that partially ablates the recipient's immune system and allows engraftment of donor bone marrow. The resulting mixed chimerism creates a state in which the recipient's new immune cells are educated in an environment containing both donor and recipient cells, leading to deletion of donor-reactive T cells. Multiple patients treated with this protocol at Massachusetts General Hospital and Stanford have been successfully weaned off all immunosuppressive drugs and maintained normal kidney function for over a decade.

Regulatory T cell-based tolerance protocols are also in clinical trials. The approach involves isolating or generating donor-specific Tregs from the recipient, expanding them in the laboratory, and infusing them around the time of transplantation to suppress donor-reactive immune responses. Early results are promising, with some patients achieving significant reductions in immunosuppressive drug requirements, though complete tolerance has not yet been reliably achieved. The development of practical, reproducible tolerance protocols remains one of the most important goals in transplant medicine.